The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding

Journal of Immunology

Volumn 177, Issue 10, 2006, Pages 7050-7058

  Yan, Pangke ^a   Nanamori, Masakatsu ^b   Sun, Meiling ^a   Zhou, Caihong ^a   Cheng, Ni ^b   Li, Na ^a   Zheng, Wei ^c   Xiao, Lihua ^c   Xie, Xin ^a   Ye, Richard D ^b   Wang, Ming Wei ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF ILLINOIS   (United States)

^c FUJIAN INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; BETA GLUCURONIDASE; BUCLADESINE; CALCIUM ION; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; CYCLOSPORIN H; FORMYLPEPTIDE RECEPTOR; IODINE 125; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TRITIUM;

ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION; CHEMOTAXIS; DEGRANULATION; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA CELL; LIGAND BINDING; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 33750841010     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.10.7050     Document Type: Article

References (40)

1. Harris, H. 1954. Role of chemotaxis in inflammation. Physiol. Rev. 34: 529 -562.
2. Snyderman, R., and R. J. Uhing. 1992. Phagocytic cells: stimulus-response coupling mechanisms. In Inflammation: Basic Principles and Clinical Correlates. J. I. Gallin, I. M. Goldstein, and R. Snyderman, eds. Raven Press, New York, pp. 421-439.
3. Boulay, F., M. Tardif, L. Brouchon, and P. Vignais. 1990. The human n-formylpeptide receptor: characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry 29: 11123-11133.
4. Murphy, P. M. 1994. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12: 593-633.
5. Prossnitz, E. R., and R. D. Ye. 1997. The N-formylpeptide receptor: a model for the study of chemoattractant receptor structure and function. Pharmacol. Ther. 74: 73-102.
6. Le, Y., P. M. Murphy, and J. M. Wang. 2002. Formyl-peptide receptors revisited. Trends Immunol. 23: 541-548.
7. Gao, J.-L., E. J. Lee, and P. M. Murphy. 1999. Impaired anti-bacterial host defense in mice lacking the N-formyl peptide receptor. J. Exp. Med. 189: 657-662.
8. Di Padova, F. E. 1990. Pharmacology of cyclosporine (sandimmune). V. Pharmacological effects on immune function: in vitro studies. Pharmacol. Rev. 41: 373-405.
9. Hess, A. D., and P. M. Colombani. 1986. Mechanism of action of cyclosporine: role of calmodulin, cyclophilin, and other cyclosporine-binding proteins. Transplant. Proc. 18: 219-237.
10. von Wartburg, A., and R. Traber. 1986. Chemistry of the natural cyclosporin metabolites. Prog. Allergy 38: 28-45.
11. Wenzel-Seifert, K., L. Grunbaum, and R. Seifert. 1991. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation. J. Immunol. 147: 1940-1946.
12. Wenzel-Seifert, K., and R. Seifert. 1993. Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine and cyclosporins A, B, C, D, and E. J. Immunol. 150: 4591-4599.
13. Wenzel-Seifert, K., C. M. Hurt, and R. Seifert. 1998. High constitutive activity of the human formyl peptide receptor. J. Biol. Chem. 273: 24181-24189.
14. Loor, F., F. Tiberghien, T. Wenandy, A. Didier, and R. Traber. 2002. Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor. J. Med. Chem. 45: 4613-4628.
15. Hultsch, T., M. W. Albers, S. L. Schreiber, and R. J. Hohman. 1991. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. Proc. Natl. Acad. Sci. USA 88: 6229-6233.
16. Morisaki, M., and T. Arai. 1992. Identity of immunosuppressant FR-900520 with ascomycin. J. Antibiot. 45: 126-128.
17. Hong, L., X. Tang, C. Miao, and Y. Wang. 1984. Studies on cyclosporins produced by Fusarium solani sp. No. 4-11: isolation, separation, purification and identification. Kangshengsu 9: 5-15.
18. Zheng, W., J. Zhou, Q. Wen, and J. Zhang. 2001. Cyclosporin H produced by Fusarium solani: purification and structure identification. Chin. J. Antibiot. 26: 417-419.
19. He, R., L. Tan, D. D. Browning, J. M. Wang, and R. D. Ye. 2000. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor. J. Immunol. 165: 4598-4605.
20. Hoyle, P. C., and R. J. Freer. 1984. Isolation and reconstitution of the N-formylpeptide receptor from HL-60 derived neutrophils. FEBS 167: 277-280.
21. Ulmer, A. J., and H. D. Flad. 1979. Discontinuous density gradient separation of human mononuclear leucocytes using Percoll as gradient medium. J. Immunol. Methods 30: 1-10.
22. 2 nicotinic acetylcholine receptor. Acta Pharmacol. Sin. 26: 1175-1180.
23. Haribabu, B., D. V. Zhelev, B. C. Pridgen, R. M. Richardson, H. Ali, and R. Snyderman. 1999. Chemoattractant receptors activate distinct pathways for chemotaxis and secretion. Role of G-protein usage. J. Biol. Chem. 274: 37087-37092.
24. Tian, Q., J. Li, X. Xie, M. Sun, H. Sang, C. Zhou, T. An, L. Hu, R. D. Ye, and M. W. Wang. 2005. Stereospecific induction of nuclear factor-κB activation by isochamaejasmin. Mol. Pharmacol. 68: 1534-1542.
25. Borregaard, N., and J. B. Cowland. 1997. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89: 3503-3521.
26. Niedel, J., I. Kahane, L. Lachman, and P. Cuatrecasas. 1980. A subpopulation of cultured human promyelocytic leukemia cells (HL-60) displays the formyl peptide chemotactic receptor. Proc. Natl. Acad. Sci. USA 77: 1000-1004.
27. Hultsch, T., K. D. Muller, J. G. Meingassner, M. Grassberger, R. E. Schopf, and J. Knop. 1998. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch. Dermatol. Res. 290: 501-507.
28. 125I-chemotactic peptide by human neutrophils. J. Biol. Chem. 254: 10700-10706.
29. Loor, F., F. Tiberghien, T. Wenandy, A. Didier, and R. Traber. 2002. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. J. Med. Chem. 45: 4598-4612.
30. 2+ fluxes in the RBL-2H3 cell line. Int. Immunopharmacol. 6: 742-749.
31. Wenzel-Seifert, K., and R. Seifert. 1993. Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations. Naunyn-Schmiedeberg's Arch. Pharmacol. 348: 7-13.
32. de Paulis, A., A. Ciccarelli, G. de Crescenzo, R. Cirillo, V. Patella, and G. Marone. 1996. Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl- phenylalanine. J. Allergy Clin. Immunol. 98: 152-164.
33. Quehenberger, O., Z. K. Pan, E. R. Prossnitz, S. L. Cavanagh, C. G. Cochrane, and R. D. Ye. 1997. Identification of an N-formyl peptide receptor ligand binding domain by a gain-of-function approach. Biochem. Biophys. Res. Commun. 238: 377-381.
34. Mills, J. S., H. M. Miettinen, D. Barnidge, M. J. Vlases, S. Wimer-Mackin, E. A. Dratz, J. Sunner, and A. J. Jesaitis. 1998. Identification of a ligand binding site in the human neutrophil formyl peptide receptor using a site-specific fluorescent photoaffinity label and mass spectrometry. J. Biol. Chem. 273: 10428-10435.
35. Miettinen, H. M., J. S. Mills, J. M. Gripentrog, E. A. Dratz, B. L. Granger, and A. J. Jesaitis. 1997. The ligand binding site of the formyl peptide receptor maps in the transmembrane region. J. Immunol. 159: 4045-4054.
36. Sklar, L. A., S. P. Fay, B. E. Seligmann, R. J. Freer, N. Muthukumaraswamy, and H. Mueller. 1990. Fluorescence analysis of the size of a binding pocket of a peptide receptor at natural abundance. Biochemistry 29: 313-316.
37. Le, Y., W. Gong, B. Li, N. M. Dunlop, W. Shen, S. B. Su, R. D. Ye, P. M. Murphy, and J. M. Wang. 1999. Utilization of two seven-transmembrane, G-protein coupled receptors FPRL1 and FPR by the synthetic hexapeptide WKYMVm for human phagocyte activation. J. Immunol. 163: 6777-6784.
38. John, U., S. Ullrich, M. Roskos, and J. Misselwitz. 2005. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. Transplant. Proc. 37: 1608-1611.
39. Teisseyre, J., M. Markiewicz, T. Drewniak, P. Kalicinski, A. Kaminski, H. Ismail, M. Szymczak, M. Teisseyre, and P. Nachulewicz. 2003. Switching cyclosporine blood concentration monitoring from C0 to C2 in children late after liver transplantation. Transplant. Proc. 35: 2287-2288.
40. Spisani, S., E. Fabbri, M. Muccinelli, A. Cariani, L. Barbin, F. Trotta, and L. Dovigo. 2001. Inhibition of neutrophil responses by cyclosporin A: an insight into molecular mechanisms. Rheumatology 40: 794-800.